Brazilian and French researchers have developed an imaging-based AI tool to predict how multiple sclerosis patients will respond to natalizumab treatment.
Key Details
- 1Combines high-content cell imaging and machine learning to analyze patient blood samples before natalizumab therapy.
- 2Study used over 400 cell morphological features, with 130 key characteristics for prediction.
- 3Tool achieved 92% accuracy in discovery and 88% in validation cohorts for predicting drug response.
- 4Non-responders showed distinct actin remodeling and cell morphology (more elongated CD8+ T cells).
- 5Findings published in Nature Communications, suggesting potential for broader disease and drug applications.
Why It Matters
This research demonstrates how imaging AI and advanced cell analysis can enable more personalized and effective treatment strategies in neurology. Such approaches could optimize resource use, reduce side effects, and accelerate precision medicine adoption in radiology and adjacent fields.
Source
EurekAlert
Related News
•EurekAlert
AI Maps Genetic Factors Shaping the Corpus Callosum via MRI Scans
USC researchers used AI to analyze MRI scans and uncover the genetic architecture of the brain's corpus callosum.
•EurekAlert
AI Accurately Detects Heart Disease via Smartwatch ECG in 600-Patient Study
An AI tool accurately detected structural heart disease from smartwatch single-lead ECGs in a 600-person prospective trial.
•EurekAlert
WashU Launches AI Imaging Center to Advance Precision Diagnostics
Washington University establishes a new center to develop AI-powered imaging tools for better diagnosis and precision medicine.